Yes, I didn't know this about MSB.
That they are seeing positive results in stage 3 trials shows that these specific MSC's can be made to improve the condition, and has implications for Cynata's product. Whether in general, MSC's such as CYP-001 can do the same needs to be confirmed by our own clinical trials.
I think that the response to CYP-001 in subjects in our GvHD trial will be viewed more in the context of other applications of Cymerus than in GvHD treatments per se.
GVHD, page-2
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
27.0¢ |
Change
0.030(12.5%) |
Mkt cap ! $48.50M | |||
| Open | High | Low | Value | Volume |
| 26.0¢ | 29.5¢ | 26.0¢ | $113.1K | 420.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4999 | 27.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 27.5¢ | 3935 | 1 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| CYP (ASX) Chart |